Lonza Pharma & Biotech is investing in a new phase of development at their Portsmouth, NH site. The expansion will include mid-scale mammalian capacity and the addition of new cell-therapy suites.   The company is installing multiple 6,000L bioreactors at the site to meet existing and new customers’ needs, with building expected to start in late 2018. Further expansion of mid-scale capacity is a key area of growth for the company driven by a favorable regulatory environment for devel...